NCT07310355 2025-12-30
68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Chengdu StarRay Therapeutics Co., Ltd
Phase 1/2 Not yet recruiting
Clinical Trials
9 trialsNCT07244393 2025-11-24
Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer
Cellbion Co., Ltd.
Phase 1 Not yet recruiting
NCT06241846 2025-08-27
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2 Recruiting
NCT07104617 2025-08-05
Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）
TYK Medicines, Inc
Phase 1/2 Not yet recruiting
NCT03903835 2025-04-09
ProBio
Karolinska Institutet
Phase 3 Recruiting
NCT06344715 2024-04-03
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
SL VAXiGEN
Phase 1 Unknown
NCT04825652 2023-01-13
177Lu-PSMA-617 Managed Access Program for mCRPC Patients
Advanced Accelerator Applications
No longer available
NCT04862091 2022-03-04
Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT03896984 2021-12-29
PHENIX
Bayer
Completed